Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase II/III Study of AL102 in Desmoid Tumors

Ayala Pharmaceuticals, Inc. announced that it has completed patient enrollment in Part A of the Phase II/III RINGSIDE clinical trial evaluating AL102 in desmoid tumors.